Interleukin-10: Role in increasing susceptibility and pathogenesis of rheumatic fever/rheumatic heart disease.

The Role of Environmental Factors in the Pathogenesis of Inflammatory Bowel Diseases: A Review

JAMA Pediatr.

Shouval DS, Rufo PA

doi: 10.1001/

Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015

N Engl J Med.

Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, Forouzanfar MH, Longenecker CT, Mayosi BM, Mensah GA, Nascimento BR, Ribeiro ALP, Sable CA, Steer AC, Naghavi M, Mokdad AH, Murray CJL, Vos T, Carapetis JR, Roth GA

doi: 10.1056/NEJMoa1603693.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

Semin Arthritis Rheum.

Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, Erra A, Serrat M, Espartal E, Antón S, Añez GA, Caparrós-Ruiz R, Pluma A, Trallero-Araguás E, Barceló-Bru M, Almirall M, De Agustín JJ, Segura JL, Julià A, Marsal S

doi: 10.1016/j.semarthrit.

Calprotectin in rheumatic diseases.

Ometto F, Friso L, Astorri D, Botsios C, Raffeiner B, Punzi L, Doria A

Vitamin D in autoimmune rheumatic diseases: A view inside gender differences.

Pharmacol Res.

Vasile M, Corinaldesi C, Antinozzi C, Crescioli C

doi: 10.1016/j.phrs.2016.12.038.

Autoimmune Disease

The potential role for infections in the pathogenesis of autoimmune Addison's disease

Clin Exp Immunol.

Hellesen A, Bratland E

doi: 10.1111/cei.13207.

EULAR ^® 2019

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Rheumatic and Musculoskeletal Diseases

Yusof et al. 2019. Predicting severe infection in repeat cycles of rituximab and effects of hypogammaglobulinemia for the treatment of rheumatic and musculoskeletal diseases. Oral presentation presented at: EULAR 2019 Congress; 12–15 June 2019; Madrid, Spain.

Autoimmune Disease

Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs

Rheumatology (Oxford).

Nakafero G, Grainge MJ, Myles PR, Mallen CD, Zhang W, Doherty M, Nguyen-Van-Tam JS, Abhishek A

doi: 10.1093/rheumatology/keaa078.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Ann Rheum Dis.

Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus EF, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham KD, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Wallace ZS, Yazdany J, Machado PM, Robinson PC, COVID-19 Global Rheumatology Alliance.

doi: 10.1136/annrheumdis-2020-217871.

Related content

The Role of Environmental Factors in the Pathogenesis of Inflammatory Bowel Diseases: A Review

Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

Calprotectin in rheumatic diseases.

Vitamin D in autoimmune rheumatic diseases: A view inside gender differences.

The potential role for infections in the pathogenesis of autoimmune Addison's disease

Rheumatic and Musculoskeletal Diseases

Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry